Navigation Links
Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
Date:6/11/2008

Lead Candidate Set for Phase II Clinicals

LA JOLLA, Calif., June 11 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), announced today that it has been granted an exclusive, worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs for the treatment of heart failure. The most advanced drug in the portfolio is expected to enter a Phase II clinical study later this year.

The drug portfolio was developed in part by Jonathan S. Stamler, M.D., George Barth Geller Professor of Research in Cardiovascular Diseases and Professor of Medicine and Biochemistry at Duke University, and Joshua M. Hare, M.D., Louis Lemberg Professor of Medicine, Chief of the Division of Cardiology and Director of the Interdisciplinary Stem Cell Institute at University of Miami. Dr. Hare was formerly associated with Johns Hopkins University.

The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.

According to the National Heart, Lung and Blood Institute (NHLBI), there are an estimated five million Americans that suffer from congestive heart failure, a condition characterized by the inability of the heart to efficiently pump blood and by fluid accumulation in the lungs and other tissues. An estimated 300,000 deaths each y
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
3. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
4. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
5. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
9. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
10. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
11. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... 2014  BC Technical, the largest nationwide, non-OEM provider ... Inc., a leading provider of Siemens Nuclear Medicine and ... naming BC Technical as the authorized provider of service ... and BC Technical announced today that the two companies ... as the service and systems provider for MiE,s camera ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 2011 ChromaDex Corporation (OTCBB: CDXC), an innovative ... and ingredients to the dietary supplement, food & ... results for the second quarter of 2011. On ... U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex ...
... NEW YORK, Aug. 11, 2011 Citeline, an Informa ... pharmaceutical clinical trials recently reviewed the findings from the ... July 16-21, 2011, noting that while pharma continues to ... ahead in terms of biomarkers and early warning for ...
Cached Medicine Technology:ChromaDex Announces Financial Results for Second Quarter 2011 2ChromaDex Announces Financial Results for Second Quarter 2011 3ChromaDex Announces Financial Results for Second Quarter 2011 4Global Standardization for Alzheimer's Biomarkers Moves a Major Step Closer to Reality 2
(Date:7/13/2014)... BC (PRWEB) July 13, 2014 Victorian ... excitement by promoting the rental of bikes for its ... historic downtown Victorian Hotel to tour the area using ... plus tax. Bicycle enthusiasts love to call Vancouver home, ... options for cycle travel and picturesque journeys through the ...
(Date:7/13/2014)... 2014 The report “Micronutrient Market ... Form (Chelated & Non Chelated), Application Mode (Soil, ... Trends and Forecast to 2018” defines and segments ... and forecasting of the global value and volume ... and restraining factors for the global agriculture micronutrients ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 According ... Processing and Computing Market by Component (processor, GPU, ... Automotive, MDA, Medical), and Geography - Forecast and ... Heterogeneous Mobile Processing & Computing Market is expected ... a CAGR of 20.75% from 2014 to 2020. ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... type of sensor for people with diabetes is being developed ... of blood, researchers report. Scientists at Brown University in ... artificial saliva. It uses light, metal and a special enzyme ... knows that diabetics have to prick their fingers to draw ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
Breaking Medicine News(10 mins):Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... , This release is available in German ... Foundation) establishes four new Research Units. This decision has just ... meeting in Bonn in April. In Research Units, outstanding researchers ... locations and across disciplines. The DFG funding thereby secures the ...
... , WEDNESDAY, April 20 (HealthDay News) -- Excessive sleeping, ... a greatly increased risk for behavioral problems later in ... describe as "regulatory problems," were the focus of an ... Data came from 16,848 children, including 1,935 with regulatory ...
... at the Mailman School of Public Health report evidence of ... deficits in IQ and working memory at age seven. ... prenatal chlorpyrifos exposure on cognitive development at the time of ... Perspectives . Until banned for indoor residential use ...
... , WEDNESDAY, April 20 (HealthDay News) -- ... family instability has no effect, a new study suggests. ... children and their families when the children were 9 ... provided insight into family poverty, family transitions, family demographics ...
... WEDNESDAY, April 20 (HealthDay News) -- Researchers have developed a ... pregnant women will deliver their babies prematurely. The ... foolproof: a study found that it misses some premature births ... an important tool for an obstetrician who currently has no ...
... , WEDNESDAY, April 20 (HealthDay News) -- Inhaled ... patients with chronic obstructive pulmonary disease, or COPD, who ... U.S. researchers examined the medical records of 15,768 ... VA hospitals for pneumonia between 2002 and 2007. Of ...
Cached Medicine News:Health News:DFG establishes 4 new research units 2Health News:DFG establishes 4 new research units 3Health News:Babies' Persistent Fussiness Could Mean Behavioral Woes Ahead 2Health News:Prenatal exposure to common insecticide linked to decreases in cognitive functioning at age 7 2Health News:Poverty Can Hinder a Child's Cognitive Development, Study Says 2Health News:Experimental Test May Warn of Premature Births 2Health News:Inhaled Meds May Save COPD/Pneumonia Patients' Lives 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: